Selective CRAF Inhibition Elicits Transactivation

Overview

Journal J Am Chem Soc

Publisher American Chemical Society

Specialty Chemistry

Date 2021 Mar 22

PMID 33750116

Citations 9

Authors

Charles W Morgan

Ian L Dale

Andrew P Thomas

James Hunt

Jason W Chin

Affiliations

Soon will be listed here.

Abstract

Discovering molecules that regulate closely related protein isoforms is challenging, and in many cases the consequences of isoform-specific pharmacological regulation remains unknown. RAF isoforms are commonly mutated oncogenes that serve as effector kinases in MAP kinase signaling. BRAF/CRAF heterodimers are believed to be the primary RAF signaling species, and many RAF inhibitors lead to a "paradoxical activation" of RAF kinase activity through transactivation of the CRAF protomer; this leads to resistance mechanisms and secondary tumors. It has been hypothesized that CRAF-selective inhibition might bypass paradoxical activation, but no CRAF-selective inhibitor has been reported and the consequences of pharmacologically inhibiting CRAF have remained unknown. Here, we use bio-orthogonal ligand tethering (BOLT) to selectively target inhibitors to CRAF. Our results suggest that selective CRAF inhibition promotes paradoxical activation and exemplify how BOLT may be used to triage potential targets for drug discovery before any target-selective small molecules are known.

Citing Articles

Genetic Code Expansion: Recent Developments and Emerging Applications.

Huang Y, Zhang P, Wang H, Chen Y, Liu T, Luo X Chem Rev. 2024; 125(2):523-598.

PMID: 39737807 PMC: 11758808. DOI: 10.1021/acs.chemrev.4c00216.

Engineering Pyrrolysine Systems for Genetic Code Expansion and Reprogramming.

Dunkelmann D, Chin J Chem Rev. 2024; 124(19):11008-11062.

PMID: 39235427 PMC: 11467909. DOI: 10.1021/acs.chemrev.4c00243.

Targeting RAF dimers in RAS mutant tumors: From biology to clinic.

Yin H, Tang Q, Xia H, Bi F Acta Pharm Sin B. 2024; 14(5):1895-1923.

PMID: 38799634 PMC: 11120325. DOI: 10.1016/j.apsb.2024.02.018.

The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.

Ryan M, Quade B, Schenk N, Fang Z, Zingg M, Cohen S Cancer Discov. 2024; 14(7):1190-1205.

PMID: 38588399 PMC: 11215411. DOI: 10.1158/2159-8290.CD-24-0139.

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.

Wang P, Laster K, Jia X, Dong Z, Liu K Mol Cancer. 2023; 22(1):208.

PMID: 38111008 PMC: 10726672. DOI: 10.1186/s12943-023-01903-x.

References

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S . Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014; 25(5):697-710. PMC: 4049532. DOI: 10.1016/j.ccr.2014.03.011. View

Samatar A, Poulikakos P . Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13(12):928-42. DOI: 10.1038/nrd4281. View

Blasco R, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J . c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell. 2011; 19(5):652-63. PMC: 4854330. DOI: 10.1016/j.ccr.2011.04.002. View

Galabova-Kovacs G, Kolbus A, Matzen D, Meissl K, Piazzolla D, Rubiolo C . ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle. 2006; 5(14):1514-8. DOI: 10.4161/cc.5.14.2981. View

Zhang C, Spevak W, Zhang Y, Burton E, Ma Y, Habets G . RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015; 526(7574):583-6. DOI: 10.1038/nature14982. View

Vauquelin G, Charlton S . Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol. 2013; 168(8):1771-85. PMC: 3623049. DOI: 10.1111/bph.12106. View

Lowinger T, Riedl B, Dumas J, Smith R . Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des. 2002; 8(25):2269-78. DOI: 10.2174/1381612023393125. View

Karoulia Z, Gavathiotis E, Poulikakos P . New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017; 17(11):676-691. PMC: 6000833. DOI: 10.1038/nrc.2017.79. View

Plass T, Milles S, Koehler C, Szymanski J, Mueller R, Wiessler M . Amino acids for Diels-Alder reactions in living cells. Angew Chem Int Ed Engl. 2012; 51(17):4166-70. DOI: 10.1002/anie.201108231. View

10.

Elsasser S, Ernst R, Walker O, Chin J . Genetic code expansion in stable cell lines enables encoded chromatin modification. Nat Methods. 2016; 13(2):158-64. PMC: 4888942. DOI: 10.1038/nmeth.3701. View

11.

Lavoie H, Therrien M . Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015; 16(5):281-98. DOI: 10.1038/nrm3979. View

12.

Baud M, Lin-Shiao E, Cardote T, Tallant C, Pschibul A, Chan K . Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014; 346(6209):638-641. PMC: 4458378. DOI: 10.1126/science.1249830. View

13.

Schumann B, Malaker S, Wisnovsky S, Debets M, Agbay A, Fernandez D . Bump-and-Hole Engineering Identifies Specific Substrates of Glycosyltransferases in Living Cells. Mol Cell. 2020; 78(5):824-834.e15. PMC: 7276986. DOI: 10.1016/j.molcel.2020.03.030. View

14.

Yanagisawa T, Ishii R, Fukunaga R, Kobayashi T, Sakamoto K, Yokoyama S . Multistep engineering of pyrrolysyl-tRNA synthetase to genetically encode N(epsilon)-(o-azidobenzyloxycarbonyl) lysine for site-specific protein modification. Chem Biol. 2008; 15(11):1187-97. DOI: 10.1016/j.chembiol.2008.10.004. View

15.

Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin J . In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006; 66(19):9483-91. DOI: 10.1158/0008-5472.CAN-05-4227. View

16.

Krishnamurthy V, Semetey V, Bracher P, Shen N, Whitesides G . Dependence of effective molarity on linker length for an intramolecular protein-ligand system. J Am Chem Soc. 2007; 129(5):1312-20. PMC: 2535942. DOI: 10.1021/ja066780e. View

17.

Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H . RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell. 2013; 23(5):594-602. DOI: 10.1016/j.ccr.2013.03.033. View

18.

Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas P . c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell. 2018; 33(2):217-228.e4. DOI: 10.1016/j.ccell.2017.12.014. View

19.

Rebocho A, Marais R . ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Oncogene. 2012; 32(26):3207-12. DOI: 10.1038/onc.2012.330. View

20.

Davis L, Chin J . Designer proteins: applications of genetic code expansion in cell biology. Nat Rev Mol Cell Biol. 2012; 13(3):168-82. DOI: 10.1038/nrm3286. View